Logo image
Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases
Journal article   Peer reviewed

Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases

Luke T. Nordquist and Neal D. Shore
Journal of clinical oncology, Vol.34(15_suppl), pp.e16546-e16546
05/20/2016

Metrics

1 Record Views

Details

Logo image